Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Since the Novo Nordisk (CSE: NOVOb) share price peaked in June last year just above the DKK 1,000 mark, it has suffered a severe setback and has now fallen by over 40%. In Decembe ...

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

Helping kids with obesity drop pounds can have a huge impact on their future health.When these children and teens los ...

The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

A gut microbe has been identified that mimics the effects of Ozempic to mitigate diabetes and obesity. Here's how to take ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...